Report cover image

Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 173 Pages
SKU # APRC20277877

Description

Summary

According to APO Research, The global Neurokinin Receptor Antagonists for Vasomotor Symptoms market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Neurokinin Receptor Antagonists for Vasomotor Symptoms is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Neurokinin Receptor Antagonists for Vasomotor Symptoms is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Neurokinin Receptor Antagonists for Vasomotor Symptoms is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Neurokinin Receptor Antagonists for Vasomotor Symptoms is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Neurokinin Receptor Antagonists for Vasomotor Symptoms include Astellas Pharma and Bayer etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Neurokinin Receptor Antagonists for Vasomotor Symptoms, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Neurokinin Receptor Antagonists for Vasomotor Symptoms, also provides the sales of main regions and countries. Of the upcoming market potential for Neurokinin Receptor Antagonists for Vasomotor Symptoms, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neurokinin Receptor Antagonists for Vasomotor Symptoms sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Neurokinin Receptor Antagonists for Vasomotor Symptoms market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Neurokinin Receptor Antagonists for Vasomotor Symptoms sales, projected growth trends, production technology, application and end-user industry.

Neurokinin Receptor Antagonists for Vasomotor Symptoms Segment by Company

Astellas Pharma
Bayer
Neurokinin Receptor Antagonists for Vasomotor Symptoms Segment by Type

Fezolinetant
Elinzanetant
Neurokinin Receptor Antagonists for Vasomotor Symptoms Segment by Application

Hospital and Clinic
Pharmacy
Other
Neurokinin Receptor Antagonists for Vasomotor Symptoms Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurokinin Receptor Antagonists for Vasomotor Symptoms market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neurokinin Receptor Antagonists for Vasomotor Symptoms and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurokinin Receptor Antagonists for Vasomotor Symptoms.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neurokinin Receptor Antagonists for Vasomotor Symptoms market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neurokinin Receptor Antagonists for Vasomotor Symptoms manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Neurokinin Receptor Antagonists for Vasomotor Symptoms in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Neurokinin Receptor Antagonists for Vasomotor Symptoms in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

173 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size, 2020 VS 2024 VS 2031
1.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Size Estimates and Forecasts (2020-2031)
1.4 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Estimates and Forecasts (2020-2031)
1.5 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market Dynamics
2.1 Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Trends
2.2 Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Drivers
2.3 Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Opportunities and Challenges
2.4 Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Restraints
3 Neurokinin Receptor Antagonists for Vasomotor Symptoms Market by Manufacturers
3.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Manufacturers (2020-2025)
3.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Manufacturers (2020-2025)
3.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Average Sales Price by Manufacturers (2020-2025)
3.4 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Manufacturers, Product Type & Application
3.7 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Market CR5 and HHI
3.8.2 Global Top 5 and 10 Neurokinin Receptor Antagonists for Vasomotor Symptoms Players Market Share by Revenue in 2024
3.8.3 2024 Neurokinin Receptor Antagonists for Vasomotor Symptoms Tier 1, Tier 2, and Tier 3
4 Neurokinin Receptor Antagonists for Vasomotor Symptoms Market by Type
4.1 Neurokinin Receptor Antagonists for Vasomotor Symptoms Type Introduction
4.1.1 Fezolinetant
4.1.2 Elinzanetant
4.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type
4.2.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Type (2020-2031)
4.2.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Type (2020-2031)
4.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type
4.3.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Type (2020-2031)
4.3.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Type (2020-2031)
5 Neurokinin Receptor Antagonists for Vasomotor Symptoms Market by Application
5.1 Neurokinin Receptor Antagonists for Vasomotor Symptoms Application Introduction
5.1.1 Hospital and Clinic
5.1.2 Pharmacy
5.1.3 Other
5.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application
5.2.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Application (2020-2031)
5.2.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Market Share by Application (2020-2031)
5.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application
5.3.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Application (2020-2031)
5.3.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Application (2020-2031)
6 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region
6.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region (2020-2031)
6.2.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Region (2020-2025)
6.2.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Region
7.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Region
7.1.1 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Region (2020-2025)
7.1.3 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue by Region (2026-2031)
7.1.4 Global Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2020-2031)
7.2.2 North America Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2020-2031)
7.3.2 Europe Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2020-2031)
7.4.2 Asia-Pacific Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Neurokinin Receptor Antagonists for Vasomotor Symptoms Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Astellas Pharma
8.1.1 Astellas Pharma Comapny Information
8.1.2 Astellas Pharma Business Overview
8.1.3 Astellas Pharma Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Astellas Pharma Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Portfolio
8.1.5 Astellas Pharma Recent Developments
8.2 Bayer
8.2.1 Bayer Comapny Information
8.2.2 Bayer Business Overview
8.2.3 Bayer Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Bayer Neurokinin Receptor Antagonists for Vasomotor Symptoms Product Portfolio
8.2.5 Bayer Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Neurokinin Receptor Antagonists for Vasomotor Symptoms Value Chain Analysis
9.1.1 Neurokinin Receptor Antagonists for Vasomotor Symptoms Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Neurokinin Receptor Antagonists for Vasomotor Symptoms Production Mode & Process
9.2 Neurokinin Receptor Antagonists for Vasomotor Symptoms Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Neurokinin Receptor Antagonists for Vasomotor Symptoms Distributors
9.2.3 Neurokinin Receptor Antagonists for Vasomotor Symptoms Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.